NEW YORK (GenomeWeb News) – Nuclea Biotechnologies and Wilex AG today announced an agreement for Nuclea to purchase Wilex Inc., a wholly owned subsidiary of Wilex AG.

Under the terms of the deal, Nuclea is purchasing all the shares of Wilex Inc. In addition to assuming all of the company's assets, Nuclea assumes responsibility for repayment of a $2.5 million loan between Wilex Inc. and Wilex AG.

Wilex AG is also eligible for single-digit royalties on net sales of Wilex Inc.'s HER2/neu and carbonic anhydrase IX, or CAIX, assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.